Table 1 Patients’ characteristics
From: Organ-specific and tumor-size-dependent responses to sunitinib in clear cell renal cell carcinoma
Characteristic | No. of patients (%) |
|---|---|
Sex | |
Male | 30 (78.9) |
Female | 8 (21.1) |
Age, y | |
Median [range] | 62 [27–81] |
ECOG performance status | |
0 | 25 (65.8) |
1 | 7 (18.4) |
> 1 | 6 (15.8) |
MSKCC risk category | |
Favorable | 8 (21.1) |
Intermediate | 20 (52.6) |
Poor | 10 (26.3) |
Target organs | |
Lung | 31 (81.6) |
Liver | 6 (15.8) |
Lymph node | 11 (28.9) |
Kidney | 15 (39.5) |
Nephrectomy | |
Yes | 30 (78.9) |
No (biopsy) | 8 (21.1) |
Prior treatments | |
None | 27 (71.1) |
Cytokines alone | 4 (10.5) |
Sorafenib ± cytokines | 7 (18.4) |